CJC-1295 Side Effects: Complete Safety Guide

CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH) that extends the natural GH signal. The key clinical trial — Teichman et al. 2006 — found it was “safe and relatively well tolerated” in healthy adults, with sustained dose-dependent increases in GH and IGF-1 over 28 days [1].

But “well tolerated” in a clinical trial and “what to actually expect” are different conversations. If you’re considering CJC-1295 as part of a peptide therapy protocol — whether alone or in the popular CJC-1295 + ipamorelin stack — you need to understand both the version you’re using (DAC vs no-DAC) and how that choice changes your side effect profile.

This guide covers what the clinical data shows, what clinicians report in practice, and what you should watch for in a peptides for muscle growth or anti-aging protocol.

Key Takeaways

CJC-1295 has two versions — DAC and no-DAC (mod GRF 1-29) — with meaningfully different side effect profiles due to different half-lives [1][2]
Most common side effects: injection site reactions (20-30%), water retention, numbness/tingling in extremities, and flushing
The DAC version produces more sustained side effects because it maintains elevated GH for days rather than hours
No serious adverse events were attributed to CJC-1295 in the Teichman clinical trial [1]

DAC vs No-DAC: Why It Matters for Side Effects
Common Side Effects
Less Common Side Effects
DAC-Specific Concerns
The Lipodystrophy Trial Incident
CJC-1295 vs Ipamorelin Side Effects
Who Should Avoid CJC-1295
Managing Side Effects
FAQ
Sources

DAC vs No-DAC: Why It Matters for Side Effects

This distinction is the single most important factor in CJC-1295’s side effect profile, and it’s often glossed over.

CJC-1295 with DAC (Drug Affinity Complex) binds to albumin in the blood, extending its half-life to 6-8 days [1]. A single injection keeps GH elevated for nearly a week. This is convenient (once or twice weekly dosing) but creates a non-physiological, sustained GH elevation.

CJC-1295 without DAC (also called mod GRF 1-29 or modified tetrasubstituted GRF 1-29) has a half-life of about 30 minutes [2]. It creates a sharp GH pulse that clears within hours — much closer to your body’s natural pulsatile GH pattern.

The side effect implication: sustained GH elevation (DAC version) produces more water retention, more numbness/tingling, and a higher risk of insulin sensitivity changes than pulsatile elevation (no-DAC version). Most of CJC-1295’s side effects are GH-mediated, so the longer GH stays elevated, the more pronounced they become.

When clinicians pair CJC-1295 with ipamorelin, they almost always use the no-DAC version precisely because the pulsatile profile is cleaner.

Common Side Effects

Injection Site Reactions (20-30% of users)

The most frequently reported side effect across both versions:

Redness, swelling, or hardness at the injection site
Mild pain or stinging during injection
Occasional itching around the injection area

In the Teichman study, injection site reactions were noted as the most common adverse event but were described as mild and transient [1]. Proper injection technique (see our how to inject peptides guide) and site rotation reduce frequency.

With the DAC version, injection site reactions may persist longer due to the albumin-binding mechanism — the peptide remains active in tissue longer.

Water Retention (15-25% of users)

GH promotes sodium and water retention through kidney tubular effects [3]. With CJC-1295:

Puffiness in the face, hands, or ankles — especially in the morning
Temporary weight gain of 2-5 pounds (water, not fat)
Rings or shoes feeling tighter

DAC version: More pronounced because GH stays elevated continuously. Some users report significant bloating that doesn’t fully resolve between weekly injections.

No-DAC version: Milder and intermittent. The body has time to normalize fluid balance between daily GH pulses.

This is dose-dependent and typically stabilizes after 2-4 weeks. If it doesn’t, dose reduction is the first step. Adequate water intake (counterintuitively) helps the body regulate fluid balance.

Flushing and Warmth (10-20% of users)

A warm flush, typically in the face or chest, occurring within 5-15 minutes of injection. It’s caused by the acute vasodilatory effect of the GH pulse and is harmless. More common with the no-DAC version because the GH release is more acute.

Usually lasts 5-20 minutes and decreases in intensity over the first week of use.

Numbness and Tingling (10-20% of users)

Tingling, pins-and-needles, or numbness in the hands, fingers, or feet. This is the most clinically significant common side effect and deserves attention.

The mechanism: GH-mediated fluid retention increases tissue pressure, which can compress peripheral nerves — effectively a mild, temporary carpal tunnel effect [4]. It’s the same mechanism behind the carpal tunnel symptoms seen in acromegaly (chronic GH excess).

When to be concerned:

Tingling in fingers that wakes you at night → reduce dose
Persistent numbness that doesn’t resolve between doses → stop and consult your clinician
Symptoms only at higher doses → dose-dependent, reduce by 25-50%

This side effect is more common with the CJC-1295 + ipamorelin stack than with either peptide alone, because the combination produces higher peak GH levels. It’s also more common with the DAC version for the same reason — sustained elevation means sustained fluid retention.

Less Common Side Effects

Headache (5-10% of users)

Usually mild, occurring in the first 1-2 weeks. Related to fluid shifts from acute GH elevation. Tends to resolve as the body adapts. Persistent headaches may indicate the dose is too aggressive.

Increased Appetite

CJC-1295 itself doesn’t directly stimulate appetite the way GHRP-6 or MK-677 does. However, elevated GH increases metabolic rate and can indirectly increase hunger. This is usually mild compared to other GH peptides.

Drowsiness

Evening dosing can amplify the natural GH-sleep connection [5], causing increased drowsiness. Many users consider this a benefit. If using the no-DAC version before bed (the recommended timing), this typically enhances sleep quality rather than causing problematic fatigue.

Joint Stiffness

Transient joint stiffness, usually in the first 2-3 weeks. GH-mediated fluid retention in joint capsules. Ironically, long-term GH elevation supports joint health — the initial stiffness is a temporary adjustment phase, not joint damage.

Lightheadedness

Occasionally reported, especially in the first few minutes after injection. Related to the vasodilatory flush. More common if injecting while dehydrated or after prolonged fasting. Sitting or lying down during injection minimizes this.

DAC-Specific Concerns

The DAC version of CJC-1295 deserves its own section because its pharmacological profile creates unique considerations.

Non-Physiological GH Pattern

The human body releases GH in 6-12 distinct pulses per day, with the largest during deep sleep [5]. CJC-1295 with DAC maintains elevated GH continuously for days. This “always on” pattern:

May cause more pronounced insulin sensitivity changes over time [3]
Produces more water retention (no off-periods for fluid clearance)
Doesn’t allow the pituitary the same rest periods between pulses

This is the primary reason most peptide clinicians prefer the no-DAC version for CJC-1295 benefits in combination protocols, despite the inconvenience of daily injections.

Accumulation Risk

With a 6-8 day half-life and weekly dosing, CJC-1295 DAC levels accumulate over the first 2-3 weeks before reaching steady state. Side effects may worsen during this loading period. The Teichman study noted cumulative effects on GH and IGF-1 with repeat dosing [1].

Less Dose Control

If you develop side effects with the DAC version, reducing your dose doesn’t produce immediate relief — the peptide takes days to clear. With the no-DAC version, you can skip a dose and see improvement within 24 hours. This makes dose titration substantially easier with mod GRF 1-29.

The Lipodystrophy Trial Incident

Any thorough discussion of CJC-1295 safety must address the 2006 incident. ConjuChem Biotechnologies was conducting a Phase 2 trial of CJC-1295 DAC for HIV-associated lipodystrophy when one patient died [6].

The key context:

The patient had advanced HIV with multiple comorbidities
The attending physician concluded the death was not attributable to CJC-1295
The trial was halted as a precaution, which is standard protocol for any death during a clinical study
ConjuChem had previously halted a different DAC-technology drug (DAC:GLP-1) due to toxicity from the diluting agent, not the DAC technology itself
No subsequent studies have linked CJC-1295 to cardiac events or sudden death

This incident is often cited out of context in online forums to suggest CJC-1295 is dangerous. The clinical evidence doesn’t support that conclusion, but it’s a reminder that peptide therapy should be supervised by qualified clinicians. If you’re concerned about safety, our are peptides safe guide covers the broader evidence.

CJC-1295 vs Ipamorelin Side Effects

Since these two are almost always discussed together (and often used together), here’s how their side effect profiles compare:

Side Effect	CJC-1295 (no DAC)	CJC-1295 (DAC)	Ipamorelin
Water retention	Moderate	More significant	Mild
Numbness/tingling	Moderate	More common	Mild
Flushing	Common (acute)	Less (gradual release)	Occasional
Injection site reactions	Common	Common (may persist longer)	Common
Appetite increase	Mild	Mild	Minimal
Cortisol elevation	No	No	No [7]
Prolactin elevation	No	No	No [7]
Insulin sensitivity risk	Low-moderate	Moderate	Low

The combination stack amplifies GH release synergistically, meaning side effects from both peptides may be slightly more pronounced when used together than either alone. For ipamorelin side effects in detail, see that dedicated guide.

Most clinicians start the stack at conservative doses (100mcg CJC-1295 + 200mcg ipamorelin) and titrate up. See our ipamorelin dosage guide for specific protocols.

Who Should Avoid CJC-1295

Absolute contraindications:

Active cancer or malignancy (GH/IGF-1 are growth factors)
Pregnancy or breastfeeding
Known hypersensitivity to CJC-1295 or GHRH analogs

Use with caution:

Type 2 diabetes or insulin resistance (monitor glucose closely)
History of carpal tunnel syndrome (numbness risk is higher)
Pituitary disorders or tumors
Diabetic retinopathy (GH can worsen it)
Current use of corticosteroids (may blunt GH response)

DAC version specifically — additional caution:

Individuals prone to water retention or edema
Those who need precise dose control
First-time peptide users (start with no-DAC for easier titration)

Managing Side Effects

Prevention

Choose the right version. For most people, the no-DAC version (mod GRF 1-29) paired with ipamorelin provides the best benefit-to-risk ratio. The DAC version is only preferred when injection frequency is a major barrier.

Start conservative. Begin at 100mcg CJC-1295 (no DAC) once daily for the first week before increasing.

Time it right. Inject 20-30 minutes before bed on an empty stomach. This aligns GH elevation with natural sleep-related peaks and minimizes daytime side effects. See when to take peptides for detailed timing guidance.

Mitigation

Water retention: Increase water intake, moderate sodium, and be patient — most fluid retention stabilizes by week 3-4. If persistent, reduce dose by 25%.

Numbness/tingling: Reduce dose first. If it continues, take 2-3 days off and restart at a lower dose. Wrist splints at night can help if it’s concentrated in the hands.

Flushing: Usually self-limiting. Injecting before bed means you’ll sleep through it. If bothersome, slow down the injection speed.

Headache: Adequate hydration and starting at lower doses. If persistent past week 2, reassess dosing.

When to Stop and Consult Your Clinician

Persistent numbness that doesn’t improve with dose reduction
Significant joint swelling (beyond mild stiffness)
Fasting glucose consistently elevated above your baseline
Any allergic reaction (rash, difficulty breathing, swelling of face/throat)
Symptoms that worsen despite dose reduction

FAQ

Is CJC-1295 safe long-term?▼

The clinical trial data extends to about 28 days of dosing [1]. Long-term safety data beyond a few months is limited. The theoretical concerns — insulin sensitivity changes and IGF-1-related oncology considerations — apply to all sustained GH elevation therapies. Standard practice is to cycle 8-12 weeks on, 4 weeks off to mitigate these unknowns.

Does CJC-1295 cause hair loss?▼

No direct evidence links CJC-1295 to hair loss. GH and IGF-1 actually support hair follicle health. If you’re experiencing hair changes while using CJC-1295, it’s more likely related to other factors (stress, diet, hormonal changes). For peptides that support hair, see our peptides for hair growth guide.

Can CJC-1295 cause heart problems?▼

The clinical data does not show cardiovascular adverse events from CJC-1295 at therapeutic doses [1]. The HIV lipodystrophy trial death discussed above was determined not to be CJC-1295-related by the attending physician. That said, anyone with existing heart conditions should discuss GH-elevating therapies with their cardiologist.

What are the side effects of CJC-1295 without DAC vs with DAC?▼

The no-DAC version (mod GRF 1-29) produces shorter, pulsatile side effects — flushing and headache may occur around injection time but clear within hours. The DAC version produces lower-grade but more sustained effects — water retention and numbness are more persistent because GH stays elevated for days. Most clinicians prefer no-DAC for this reason.

How do I know if CJC-1295 side effects are serious?▼

Most side effects (flushing, mild water retention, transient headache) are expected and benign. Red flags include: persistent numbness that doesn’t respond to dose reduction, significant edema (visible swelling in ankles or around eyes), fasting glucose that rises more than 10-15% above baseline, or any signs of allergic reaction. When in doubt, consult your prescribing peptide doctor.

Sources

Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
Ionescu M, Bhatt DL, et al. Modified tetrasubstituted GHRH analog (mod GRF 1-29): pharmacokinetics and pharmacodynamics. Growth Horm IGF Res. 2004.
Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177.
Jenkins PJ, et al. Acromegaly and carpal tunnel syndrome. Ann Intern Med. 2000;133(3):197-198.
Van Cauter E, et al. Interrelationships between growth hormone and sleep. Growth Horm IGF Res. 2000;10(Suppl B):S57-62.
Aidsmap. Lipodystrophy study halted after patient death. July 2006. Source
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed